Cervical Myelopathy Clinical Trial
Official title:
CSS-Assessing the Course of Degenerative Cervical Spinal Stenosis Using Functional Outcomes
Verified date | October 2023 |
Source | University Hospital, Basel, Switzerland |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The study will consist of two parts: - In Study A, objectively assessed physical activity, gait, balance, range of movement of specific joints during walking and neurophysiological findings between patients with cervical spine stenosis (CSS) without myelopathy who will be treated conservatively and patients with stenosis and signs of myelopathy who are candidates for surgical Treatment will be compared. - In Study B, the 6-month changes in the same outcomes in patients treated conservatively (from the first specialist consultation until 6 months later) and in patients treated surgically (preoperative day and 6-month post-operatively) will be quantified.
Status | Enrolling by invitation |
Enrollment | 60 |
Est. completion date | September 2025 |
Est. primary completion date | September 2025 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age > 18 years - Diagnosis of degenerative cervical spine stenosis defined by MRI (stenosis grade 2 or grade 3 - Local clinical symptoms due to degenerative changes of the cervical vertebral column with or without clinically defined myelopathy Exclusion Criteria: - Stenosis after trauma or neoplasm - Prior decompressive surgery - Previous spine or extremity surgery with a consequent sensorimotor impairment - Other pathologies than cervical spine stenosis causing gait disturbance - BMI > 35 kg/m2 - Use of walking aids - Inability to provide informed consent - Contraindications for recording of Motor evoked potentials (MEP) - Contraindications to safely undergo MRI |
Country | Name | City | State |
---|---|---|---|
Switzerland | Universitätsspital Basel | Basel |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Basel, Switzerland |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Difference in gait symmetry | The subjects will perform an instrumented gait analysis on an overground walkway with two embedded force plates | approximate duration: 30 minutes. Assessment will be performed at visit 1 and will be repeated 6 months after study inclusion at visit 2 | |
Primary | Change in balance performance | Balance performance will be assessed using the modified clinical test of sensory integration of balance (m-CTSIB) using the Biodex Balance System SD | approximate duration: 30 minutes. Assessment will be performed at visit 1 and will be repeated 6 months after study inclusion at visit 2. | |
Primary | Difference in neurophysiological outcome | Quantitative score of Motor evoked potentials (MEP) and Somato-sensory evoked potentials (SEP) | approximate duration: 30 minutes. Assessment will be performed at visit 1 and will be repeated 6 months after study inclusion at visit 2. | |
Secondary | Difference in daily physical activity | daily physical activity will be objectively monitored for 7 consecutive days using the ActiGraph wGT3X-BT (ActiGraph Corp, Pensacola Florida, USA) worn around the hip | monitored for 7 consecutive days at visit 1 or 1 week before surgery and 6 months later at visit 2 | |
Secondary | Difference in spinal cord gray and white matter areas | Participants will be investigated on the 3 Tesla (3T) whole body MRI research scanner using 2D-Averaged Magnetization Inversion Recovery Acquisitions (AMIRA) imaging | approximate duration of the scan: 30. Assessment will be performed at visit 1 and will be repeated 6 months after study inclusion at visit 2 (Measurement at visit 2 only in patients with cervical spine stenosis treated conservatively). | |
Secondary | Change in segmental quantitative muscle strength | assessments of segmental muscle force via hand-held-dynamometry following the Treatment Research Initiative to Cure ALS (TRICALS) Protocol Isometric Strength Testing 2016 at each study visit | approximate duration: 10 minutes. Assessment will be performed at visit 1 and will be repeated 6 months after study inclusion at visit 2. | |
Secondary | Change in 25-foot walk test | time of 25-foot walk test | approximate duration: 3 minutes. Assessment will be performed at visit 1 and will be repeated 6 months after study inclusion at visit 2. | |
Secondary | Change in 6-minute walk test | distance of 6-minute walk test | approximate duration: 6 minutes. Assessment will be performed at visit 1 and will be repeated 6 months after study inclusion at visit 2. | |
Secondary | Change in dynamic stability and range of motion during walking | Subjects will first complete overground walking trials in their own shoes at normal and fast walking speed while naming months backward in a 25-m hallway while gait CSS Study Protocol Version 2, 15.8.2019 Page 12 of 21 kinematics will be recorded using the RehaGait system. Afterwards, patients will be asked to walk over the force plates in the laboratory at their preferred walking speed while kinematic, kinetic and Electromyography (EMG) data will be recorded. | approximate duration: 20 minutes. Assessment will be performed at visit 1 and will be repeated 6 months after study inclusion at visit 2. | |
Secondary | Change in pain | Numeric Pain Rate Scale (NPRS), a subjective measure in which individuals rate their pain on an eleven-point numerical scale. The scale is composed of 0 (no pain at all) to 10 (worst imaginable pain) | approximate duration: 2 minutes. Assessment will be performed at visit 1 and will be repeated 6 months after study inclusion at visit 2. | |
Secondary | Change in function | Modified Japanese Orthopaedic Association - Scoring System (mJOA) questionnaire, This scale consists of four domain scores motor dysfunction in the upper extremities, motor dysfunction in the lower extremities, sensory function in the upper extremities and bladder function. Each scale ranges from 0 to 7, 5, 3, and 3, respectively, with a total score of 0 to 18.
The severity of myelopathy is defined as mild if the mJOA score is 15 or larger, moderate if the mJOA score ranges from 12 to 14 or severe if the mJOA score is less than 12 |
approximate duration: 13 min. Assessment will be performed at visit 1 and will be repeated 6 months after study inclusion at visit 2 | |
Secondary | Change in disability | Neck Disability Index (NDI) questionnaire, a Patient-completed, condition-specific functional status questionnaire with 10 items including pain, personal care, lifting, reading, headaches, concentration, work, driving, sleeping and recreation.
The NDI has sufficient support and usefulness to retain its current status as the most commonly used self-report measure for neck pain. A score of 0-4 points means no disability, 5-14 points mild disability, 15-24 points moderate disability, 25-34 points severe disability, 35-50 points complete disability |
approximate duration: 5 minutes. Assessment will be performed at visit 1 and will be repeated 6 months after study inclusion at visit 2. | |
Secondary | Change in risk of falling | The Berg Balance Scale (BBS) is a subjective measure for balance and risk of falling. Based on 14 items, vestibular function, balance ability, proprioception and muscle strength are assessed. The cut-off value for an elevated risk of falling is at 38 of 56 points. Older persons with a score of 45 of 56 points are able to ambulate safely and independently. | approximate duration: 10 minutes. Assessment will be performed at visit 1 and will be repeated 6 months after study inclusion at visit 2. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03695848 -
Prognostic Value of DTI and fMRI of Cervical Myelopathy
|
||
Terminated |
NCT00974623 -
Bone Graft Materials Observational Registry
|
N/A | |
Recruiting |
NCT05163639 -
Spinal Cord Associative Plasticity Study
|
Early Phase 1 | |
Recruiting |
NCT05183971 -
Proprioceptive Deficits in Degenerative Cervical Myelopathy
|
||
Completed |
NCT02125981 -
The Study About the Efficacy of Oral Limaprost After Surgery for Cervical Myelopathy
|
Phase 3 | |
Withdrawn |
NCT04315090 -
Post-surgical Outcomes Measure Using the ERAS Protocol for Posterior Cervical Decompression and Fusion
|
||
Not yet recruiting |
NCT05099627 -
Machine Learning Diagnosis and Prediction for Cervical Myelopathy
|
||
Completed |
NCT04173923 -
Long Term Follow-up of Cervical Myelopathy Inpatients Treated With Integrated Complementary and Alternative Medicine
|
||
Enrolling by invitation |
NCT05066711 -
NuVasive® ACP System Study
|
||
Enrolling by invitation |
NCT04770571 -
Posterior Cervical Fixation Study
|
||
Terminated |
NCT02758899 -
Diabetes and Glycosylation in Cervical Spondylosis
|
||
Completed |
NCT04962256 -
ERAS in Posterior Approach of Cervical Spine Operation
|
||
Completed |
NCT04320043 -
Adjacent Segment Disease After Anterior Cervical Decompression Surgery
|
||
Recruiting |
NCT05446259 -
Degenerative Cervical Myelopathy Repository
|
||
Completed |
NCT03304236 -
Motion Analysis of the Myelopathy Hand: New Insight Into the Classical Sign
|
||
Completed |
NCT02842775 -
Clinical Evaluation and Rehabilitation System for Dynamic Balance Control in Cervical Myelopathy Patients
|
N/A | |
Completed |
NCT01027546 -
Effect of Tranexamic Acid on Reducing Postoperative Blood Loss in Cervical Laminoplasty
|
N/A | |
Recruiting |
NCT03950349 -
FUSION EVALUATION AFTER ANTERIOR CERVICAL DISCECTOMY AND FUSION WITH STAND ALONE LOCKING CAGE WITH BLADE HRCC®
|
||
Recruiting |
NCT04968639 -
The Characteristic of Axial Pain and EEG Analysis of Patients After Laminoplasty
|
||
Enrolling by invitation |
NCT05762055 -
Prospective Comparative Analysis of ACDF vs Fusion Interbody Cages With nanoLOCK Osseointegrative Technology
|
N/A |